SIGUIENTE ... : " IDEAYA BIOSCIENCES HA INICIADO UNA COLABORACIÓN CLÍNICA Con ASTRAZENECA " Para Probar el Conjugado Anticuerpo-Fármaco en Fase de Investigación IDE849 , Dirigido Contra la Proteína DLL3 TOP1 , Junto Con el Inhibidor de PD-L1 DURVALUMAB ( IMFINZI de ASTRAZENECA ) , en PACIENTES con SMALL CELL LUNG CANCER EXTENSIVE-STAGE .... ¿ PORQUE NO ELIGIERON AL ATEZOLIZUMAB ... ?
14 noviembre 2010
Instituto Nacional del Cancer de EEUU Publica el 5 Nov. el Status de " Completed " el ensayo de Fase II del Yondelis para tratar el Sarcoma Infantil .
ClinicalTrials Identifier: NCT00070109 Updated: 2010_11_05
Descriptive Information
Brief title Ecteinascidin 743 in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors
Official title A Phase II Study Of Trabectedin (ET-743, Yondelis®) in Children With Recurrent Rhabdomyosarcoma, Ewing Sarcoma, or Nonrhabdomyosarcomatous Soft Tissue Sarcoma
Recruitment Information
Status Completed
Start date 2008-01
Primary completion date 2010-10 (Actual)
Administrative Data
Organization name National Cancer Institute (NCI)
Organization study ID CDR0000329999
Secondary ID COG-ADVL0221
Sponsor Children's Oncology Group
Collaborator National Cancer Institute (NCI)
Health Authority United States: Federal Government
...
Suscribirse a:
Comentarios (Atom)